The deal sees ANI Pharmaceuticals pay $52.5m (€47.2m) Amerigen Pharmaceuticals in cash, with an additional $25m in contingent profit share payments to be made over the next four years.
Through the deal, ANI will take responsibility for 10 commercial products, three approved products with launches pending, four filed products and four in-development products, as well as a license to commercialize two approved products.
Amerigen’s generics portfolio in the US includes fenofibrate capsules, also known by the brand name Tricor, and indapamide tablets, generic versions of Lozol tablets.
The transaction sees Amerigen divest the bulk of the rights to its US portfolio, though it also holds access to the Chinese market for the treatments. The company manufactures its products from its facility located in Suzhou, China.
The transaction continues expansion by ANI, which recently launched a contract development and manufacturing organization (CDMO) known as ANI Global Source, following a deal for WellSpring Pharma.
In addition, the company launched, or was a partner on the launch of, seven generic products during the course of 2019, including ranitidine capsules.
The company’s CEO, Arthur Przybyl, stated that it will leverage its warehousing, distribution, manufacturing and packaging capabilities to create synergies on this latest acquisition.